Kidney Disease and Cancer Risk in Patients with Venous Thromboembolism: What Does It Mean for Clinical Practice?

Abstract

Non applicable for this type of article

Thrombosis and Haemostasis 2023 Editors' Choice Papers

“…60 This study should alert physicians to be vigilant when focusing on kidney disease alone, as it could point to additional comorbidities and should reinforce existing guidelines recommending follow-up for patients 3 to 6 months postacute VTE potentially including cancer screening. 61 Other studies assessed safety of specific anticoagulation management in cancer patients. A retrospective review 62 indicated that both rivaroxaban and apixaban exhibited comparable effectiveness and safety in treating cancer-associated thrombosis over a 6-month period, suggesting the most suitable anticoagulant should be considered with regard to patient preferences, adherence, and individual patient-specific factors.…”